Insider Buying: NewGenIvf Group (NASDAQ:NIVF) Director Buys $665,000.00 in Stock

NewGenIvf Group Limited (NASDAQ:NIVF) Director Kong Yiu Cheung acquired 500,000 shares of the business’s stock in a transaction dated Tuesday, June 2nd. The stock was acquired at an average cost of $1.33 per share, for a total transaction of $665,000.00. Following the transaction, the director owned 722,223 shares of the company’s stock, valued at $960,556.59. This represents a 225.00% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Kong Yiu Cheung also recently made the following trade(s):

• On Monday, July 27th, Kong Yiu Cheung bought 2,500,000 shares of NewGenIvf Group stock. The shares were acquired at an average price of $1.00 per share, with a total value of $2,500,000.00.
• On Thursday, June 18th, Kong Yiu Cheung bought 500,000 shares of NewGenIvf Group stock. The stock was acquired at an average cost of $1.33 per share, with a total value of $665,000.00.

NewGenIvf Group Price Performance

Shares of NASDAQ:NIVF opened at $1.14 on Friday. The company’s 50-day moving average price is $2.71 and its two-hundred day moving average price is $10.90. NewGenIvf Group Limited has a one year low of $1.11 and a one year high of $1,539.00. The company has a debt-to-equity ratio of 0.16, a current ratio of 3.12 and a quick ratio of 2.98.

Analyst Upgrades and Downgrades

NIVF has been the subject of several recent research reports. Weiss Ratings reissued a “sell (d)” rating on shares of NewGenIvf Group in a research report on Friday, July 24th. Wall Street Zen upgraded NewGenIvf Group to a “hold” rating in a research note on Saturday, July 4th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock has a consensus rating of “Sell”.

About NewGenIvf Group

NewGenIVF Group Inc, trading on NASDAQ under the symbol NIVF, is an integrated provider of reproductive medicine services in the People’s Republic of China. The company operates a network of fertility clinics across major Chinese cities, delivering comprehensive infertility diagnosis and treatment to patients and couples. Its facilities are equipped with modern laboratories and surgical suites designed for assisted reproductive procedures.

NewGenIVF’s service offerings encompass a wide range of assisted reproductive technologies (ART), including in vitro fertilization (IVF), intracytoplasmic sperm injection (ICSI), preimplantation genetic testing (PGT), and fertility preservation through ovarian tissue and gamete cryopreservation.